Forte Biosciences, Inc. (FBRX) |
| 28.44 -0.06 (-0.21%) 02-25 16:00 |
| Open: | 28.75 |
| High: | 29.44 |
| Low: | 27.83 |
| Volume: | 458,280 |
| Market Cap: | 356(M) |
| PE Ratio: | -355.5 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 35.62 |
| Resistance 1: | 32.14 |
| Pivot price: | 29.59 |
| Support 1: | 26.50 |
| Support 2: | 22.05 |
| 52w High: | 35.62 |
| 52w Low: | 4.9 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Financials
| EPS | -0.080 |
| Book Value | 4.720 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -58.1 |
| Return on Equity (ttm) | -110.7 |
Company news
Wed, 25 Feb 2026
Forte Biosciences (FBRX) Raised to Buy: Key Information You Need - Bitget
Wed, 25 Feb 2026
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Mon, 09 Feb 2026
Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan
Sun, 04 Jan 2026
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock - Yahoo Finance
Sat, 03 Jan 2026
Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses - simplywall.st
Mon, 22 Dec 2025
New Forte Biosciences hire receives options for 75,000 shares - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
